Cancers connected with mutations in RET proto-oncogene: Minireview

Neoplasma

Volumn 48, Issue 5, 2001, Pages 325-331

  Altanerova, V ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

MEN 2 syndrome; RET proto oncogene

Indexed keywords

CARCINOGENESIS; DISEASE ASSOCIATION; FAMILIAL CANCER; GENE MUTATION; GENETIC SCREENING; HUMAN; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE RET; PHEOCHROMOCYTOMA; PROPHYLAXIS; SHORT SURVEY; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 0035206514     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (73)

1. Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease
2. The GDNF family ligands and receptors - Implications for neural development
3. A new hot spot for mutations in the ret proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A
4. RET mutations in exons 13 and 14 of FMTC patients
5. Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation
6. Single missense mutation in the tyrosine kinase catalytic domain of the RET proto-oncogene is associated with multiple endocrine neoplasia type 2B
7. RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer
8. Hirschsprung disease in MEN 2A: Increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation
9. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
10. Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts
11. The clinical and screening age-at-onset distribution for the MEN-2 syndrome
12. Mutations of the RET proto-oncogene in Hirschsprungs disease
13. RET in human development and oncogenesis
14. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
15. Mutations in the RET proto-oncogene the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas
16. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC
17. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours
18. Thyroid cancer: Epidemiological study of thyroid cancer in A-bomb survivors from extended life span study cohort in Hiroshima
19. Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity
20. A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma
21. Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation
22. Multiple endocrine neoplasia type 2 and RET: From neoplasia to neurogenesis
23. RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia
24. A novel point mutation in the intracellular domain of the ret proto-oncogene in the family with medullary thyroid carcinoma
25. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
26. Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A
27. A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A
28. Prevalence of pheochromocytoma hyperparathyroidism in multiple endocrine neoplasia type 2A: Results of long-term follow-up
29. Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma and Hirschsprung's disease phenotype
30. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily
31. Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain
32. The RET proto-oncogene in human cancers
33. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF
34. Thyroid cancer after Chernobyl
35. Thyroid cancer rises after Chernobyl
36. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): Mutation analysis in Japanese patients with MTC
37. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident
38. Analysis of RET proto-oncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas
39. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons
40. Mutations in the RET proto-oncogene in sporadic pheochromocytomas
41. Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities
42. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10
43. Development of medullary thyroid carcinoma in transgenic mice expressing the RET proto-oncogene altered by a multiple endocrine neoplasia type 2A mutation
44. Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation
45. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
46. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
47. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: Report of the International RET Mutation Consortium
48. Characterization of RET proto-oncogene 3'splicing variants and polyadenylation sites: A novel C-terminus for RET
49. The physical map of the human RET proto-oncogene
50. Oncogenic activation by two distinct FMTC mutations affecting the tyrosine kinase domain
51. Cys 618 Arg mutation in the RET proto-oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting
52. A novel 9-base pair duplication in RET exon 8 in familial medullary thyroid carcinoma
53. Risk estimation and screening in families of patients with medullary thyroid carcinoma
54. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome
55. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease
56. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease
57. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies
58. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
59. Different mutations of the RET gene cause different human tumoral diseases
60. Thyroid cancer among persons given X-ray treatment in infancy for an enlarged thymus gland
61. The human proto-oncogene ret: A communicative cadherin?
62. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene
63. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
64. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus
65. Germline mutation of RET codon 883 in two cases of de novo MEN 2B
66. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice
67. Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line
68. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence
69. Ret transforming gene encodes a fusion protein homologous to tyrosine kinases
70. Activation of a novel human transforming gene, ret, by DNA rearrangement
71. Cadherin cell adhesion receptors as a morphogenetic regulator
72. Characterization of a multicomponent receptor for GDNF
73. Characterization of ret oncogenic activation in MEN2 inherited cancer syndromes